Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. - Wikidata - awgldk - TriplyDB

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

http://www.wikidata.org/entity/Q34332659

about

Prevention of vertical transmission of HIV-1 in resource-limited settings The spread, treatment, and prevention of HIV-1: evolution of a global pandemic Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection The emergence of HIV transmitted resistance in Botswana: "when will the WHO detection threshold be exceeded?"Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy Transmitted minority drug-resistant HIV variants: a new epidemic?Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission Highly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in Japan Temporary treatment during primary HIV infection does not affect virologic response to subsequent long-term treatment Development of Nevirapine Resistance in Children Exposed to the Prevention of Mother-to-Child HIV-1 Transmission Programme in Maputo, Mozambique Simplified Paper Format for Detecting HIV Drug Resistance in Clinical Specimens by Oligonucleotide Ligation Pregnancy and virologic response to antiretroviral therapy in South Africa Impact of nevirapine (NVP) plasma concentration on selection of resistant virus in mothers who received single-dose NVP to prevent perinatal human immunodeficiency virus type 1 transmission and persistence of resistant virus in their infected childr Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants Progress in prevention of mother-to-child transmission of HIV infection in Ukraine: results from a birth cohort study.Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance.Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention.Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation Detection of HIV-1 drug resistance in women following administration of a single dose of nevirapine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay.Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.Post-trial access to antiretrovirals: who owes what to whom?Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.Evaluation of intra-host variants of the entire hepatitis B virus genome Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.Minority variants of drug-resistant HIV.Peripartum nevirapine exposure and subsequent clinical outcomes among HIV-infected women receiving antiretroviral therapy for at least 12 months.Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine

P2860

Q22241479-09F255E2-6B13-4BFE-A230-7932ABBA0D24 Q22241890-5B2B3F1E-F9F9-4503-9AA8-29512197252E Q24235500-191628D9-2424-47A5-B5B1-471DC547695C Q24243146-E730729E-C250-4E8B-BCF3-EF37A4E79CD2 Q28469108-C4205B5A-D053-4C08-B857-FEF5C12C3926 Q28469253-1B3D3966-A73C-4B37-A880-05769E8FA726 Q28472889-1123CD72-7858-4244-A3F7-819445C5411C Q28473296-75B001D9-2A3B-414D-852A-3BF572345761 Q28473302-CBB4A658-4923-4E6C-84BE-C1FAE0DA3B93 Q28476329-3EE17029-4823-44C1-BF02-815F024A3B72 Q28478377-B73232D9-38F5-40AC-933F-D564AF8199DB Q28478779-0E5A7208-FBA1-4E0C-9F83-E818E5246B7C Q28481233-D57F4F3A-D053-4996-ABE7-20536D8C8F97 Q28537608-332E3F5B-DAE1-497D-9B70-19D8CDDBA6A8 Q28541870-80F103F8-2213-4A35-B5A6-BBC3DA546268 Q28546418-DE3C5ECB-C130-4BF9-B022-9F19A380EFD6 Q28552499-30705067-443A-4241-9700-6DC9AADF25FB Q28741879-063D9F41-9F05-497E-B4F2-B9C799F3DFBB Q33267065-AB1A7A40-D533-4429-832B-16A0B6703FFF Q33284135-D4810B13-7B45-4619-AA9C-E6C79FE9B11C Q33396950-C99A98A7-3978-4FED-92AD-36B367779E6C Q33427616-B65D4722-B71E-44DF-9468-65D1AEAE6379 Q33512906-953AE916-B6ED-44FC-A284-41673C014EDA Q33601530-A74CF4AC-BF55-42AD-829C-921656796E58 Q33605273-175B5017-074A-40DC-92BB-461A166F2777 Q33686931-CEDEE61C-3188-42B4-A287-13D177FF0428 Q33739249-01AC4516-550D-4303-84CD-7E17022267B0 Q33749434-A5F86675-A590-446B-AB65-3E263880A5B6 Q33798282-685B21AA-B9BA-44C4-A7DA-C139981FA9F0 Q33814942-3B0A9204-C60F-4576-A9B3-6BD59BE53ABB Q33826308-BAF03A19-5912-4226-8C7A-5EE5BB485A8E Q33827080-3E5717EC-2377-4B2D-8D07-4715BAD30759 Q33827841-2C40E957-C9C8-424B-905D-73D30CF6AB2F Q33939058-AFF65DC9-2442-4E1F-9C50-A66950F0F177 Q34019433-FD711833-70B0-4335-ACA4-DDFA50072031 Q34032030-568886EF-67FF-4BA2-B4A7-6DF7806E3A5E Q34033166-DE7C45B3-B74A-416A-BD37-2574712A4E0A Q34047780-0F03E76E-BA1B-45E4-AB1B-4668802EAA28 Q34065414-A9BCD700-0CEB-44A1-AC35-2DA83578E344 Q34071112-DD81B14B-33FE-4295-B36F-8D3E77A9C61A

P2860

Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

http://www.wikidata.org/entity/Q34332659

description

2004 nî lūn-bûn

@nan

2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@ast

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@en

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@nl

type

label

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@ast

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@en

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@nl

prefLabel

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@ast

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@en

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@nl

P1433

Q34332659-0BF76638-3FDB-49C4-8869-05854A35F2B4

P1476

Q34332659-FF681B6A-A269-4558-9B13-10B5AEFB5CB8

P2093

Q34332659-02921B38-2F7F-48F2-BEED-E8A64C7B7FAA

Q34332659-3CD6BEC7-0C96-4F79-BF19-8778997FF081

Q34332659-46A965CD-A3B0-45AC-9F4B-DA669F2DB688

Q34332659-4B73B972-AD73-4A36-9CB2-279E7ABE238B

Q34332659-7F982450-26C0-4DBD-B9C9-F33A7C15DE54

Q34332659-AB2EEF7C-6B5C-46EA-9D95-BCFE588FE9E4

Q34332659-B369CFB2-8F46-4959-96CB-A48667FF3468

Q34332659-D1B60C63-7186-4559-8B30-7FD50DEF0F28

P304

Q34332659-14162EA9-C2DF-4CD7-84D4-E6F7337B32C3

P31

Q34332659-26F34CD4-DEBD-449D-BC45-6DD659D919B9

P356

Q34332659-9352ABEE-B103-46B9-8A8E-D2E1B2578328

P407

Q34332659-C0754509-900B-41B3-8EA9-FF2DCD730138

P433

Q34332659-98083B80-9DEB-4517-936D-5D3B929D0CD0

P478

Q34332659-3BE08022-132D-4C4B-AAA3-A4D280E92F14

P50

Q34332659-4515337B-888B-434A-B57B-D0B997058D98

Q34332659-D824DBB0-AD93-4BE4-A532-F14521E0F424

Q34332659-EB540644-A359-4E2B-A79E-508A02B7B24A

Q34332659-EF0CA0F2-3BE3-4D08-A2F6-978A3FCFC05F

P577

Q34332659-4DFB25F4-FEE2-4B28-94B2-35187FF62CF6

P698

Q34332659-6042726B-187A-403F-95D3-AAD736347368

P921

Q34332659-40896477-6855-44C4-B860-AA2CF796D7C2

P356

P1433

The New England Journal of Medicine

P1476

Intrapartum exposure to nevira ...... -based antiretroviral therapy.

@en

P2093

Chureeratana Bowonwatanuwong

http://www.w3.org/2001/XMLSchema#string

Pacharee Kantipong

http://www.w3.org/2001/XMLSchema#string

Perinatal HIV Prevention Trial Group

http://www.w3.org/2001/XMLSchema#string

Pranee Leechanachai

http://www.w3.org/2001/XMLSchema#string

Prattana Leenasirimakul

http://www.w3.org/2001/XMLSchema#string

Scott Hammer

http://www.w3.org/2001/XMLSchema#string

Sophie Le Coeur

http://www.w3.org/2001/XMLSchema#string

Surabhon Ariyadej

http://www.w3.org/2001/XMLSchema#string

P304

229-240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA041305

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

351

http://www.w3.org/2001/XMLSchema#string

P50

Gonzague Jourdain

Chureeratana Bowonwatanuwong

Nicole Ngo-Giang-Huong

P577

2004-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15247339

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug